Begin main content

eculizumab

Last Updated: March 1, 2019
Result type: Reports
Project Number: SR0605-000
Product Line: Common Drug Review

Generic Name: eculizumab

Brand Name: Soliris

Manufacturer: Alexion Pharma Canada Corp.

Indications: generalized Myasthenia Gravis (gMG)

Manufacturer Requested Reimbursement Criteria1:

​Soliris is indicated in adult patients with generalized Myasthenia Gravis (gMG).

Submission Type: New Indication

Project Status: Pending

Call For Patient Input: March 1, 2019

Patient Input Closed: April 22, 2019

Anticipated Date: April 3, 2019

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.